Medicamen Organics Ltd Financials
Company Logo

Medicamen Organics Ltd Financial Statement

Medicamen Organics Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

No Data Available

Medicamen Organics Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual25.27
Operating Expenses Annual20.53
Operating Profit Annual4.76
Interest Annual0.65
Depreciation0.72
Net Profit Annual2.40
Tax Annual0.98

Medicamen Organics Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning0.44
Cash Flow from Operations-3.69
Cash Flow from Investing-0.33
Cash Flow from Financing4.01
Cash Flow at the End0.43

Medicamen Organics Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)18.84
PBIT Margin (%)15.99
PBT Margin (%)-8.55
Net PROFIT Margin (%)9.50
Return On Networth / Equity (%)19.87
Return On Networth /Employed (%)16.44
Return On Assets (%)9.78
Total Debt / Equity (X)1.01
Asset Turnover Ratio (%)1.03

Medicamen Organics Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual10.35
Total Current Assets Annual27.31
Non Current Assets Annual11.27
Total Shareholders Funds Annual15.18
Total Assets Annual38.58

Medicamen Organics Ltd Earning Calls

No Data Availabe

Get Your FAQs Right

As of Nov 5, 2024, Medicamen Organics Ltd has a market capitalization of - Cr. Value Research classifies it as a Micro-Cap company.
No, Medicamen Organics Ltd is not debt-free with a debt-to-equity ratio of 0.83.
In FY 2023 , Medicamen Organics Ltd recorded a total revenue of approximately 25.27 Cr marking a significant milestone in the company's financial performance.
Medicamen Organics Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately NaN% and 0.1% annually, respectively..
Medicamen Organics Ltd's current PE ratio is undefined.
Medicamen Organics Ltd's ROCE averaged 9.4% from the FY ending March 2022 to 2024, with a median of 9.5%. It peaked at 14.5% in March 2024, reflecting strong capital efficiency over the period..
Medicamen Organics Ltd's latest EBIT is Rs. 4.04 Cr, surpassing the average EBIT of Rs. 2.25 Cr over the 5 years..